Insulin Glargine-aglr Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Insulin Glargine-aglr Injection (injection) from Eli Lilly And Co. with status To Be Discontinued. The shortage was first posted on Sep 1, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Eli Lilly And Co.
- Package NDC
- 0002-8980-05
- Dosage Form
- Injection
- Presentation
- Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
- Initial Posting
- Sep 1, 2026